Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Semglee (Insulin Glargine-yfgn) is a long-acting basal insulin analog manufactured by Mylan (Viatris). It is an interchangeable biosimilar to Lantus, meaning it can be substituted at the pharmacy without requiring a new prescription from your doctor. Semglee is FDA-approved to improve blood sugar control in adults and children (ages 6 and older) with Type 1 diabetes and adults with Type 2 diabetes. It provides steady insulin coverage for approximately 24 hours with once-daily dosing.
Semglee contains Insulin Glargine-yfgn, which forms tiny microprecipitates when injected under the skin. These microprecipitates dissolve slowly, providing a steady, prolonged release of insulin over approximately 24 hours. The insulin works by helping cells in your muscles and fat tissue absorb glucose from the bloodstream, while also reducing the amount of glucose your liver produces. This basal (background) insulin coverage helps maintain stable blood sugar levels between meals and overnight.
Dosing is individualized. For Type 2 diabetes, a typical starting dose is 10 units once daily or 0.2 units/kg/day. For Type 1 diabetes, basal insulin typically makes up about one-third of the total daily insulin requirement.
Semglee has experienced intermittent supply disruptions since 2023, with some pharmacies reporting limited availability of certain pen presentations. As a biosimilar insulin glargine product, availability can vary regionally. We rate Semglee's findability at 65 out of 100, meaning you may encounter occasional stock issues depending on your area and preferred formulation. Calling ahead to your pharmacy or checking multiple locations is recommended.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Semglee can be prescribed by a range of healthcare providers, including:
Telehealth consultations are also available for insulin management in many states.
No, Semglee is not a controlled substance. It is not scheduled by the DEA. However, insulin is a prescription medication and must be prescribed by a licensed healthcare provider. In some states, insulin may be available without a prescription in emergency situations, but this varies by state law.
Serious side effects include severe hypoglycemia (confusion, seizures, loss of consciousness), hypokalemia (low potassium), and increased risk of heart failure when used with thiazolidinediones.
Always inform your prescriber of all medications, supplements, and alcohol use.
Semglee is an important and more affordable option for patients who need long-acting basal insulin. As the first interchangeable biosimilar to Lantus, it offers the same clinical effectiveness at a lower price point — with cash prices as low as $80–$150 using discount cards, and copays as low as $0–$35 with the manufacturer savings card. While intermittent supply issues mean it scores a 65 on our findability scale, most patients can locate it by checking multiple pharmacies or asking their pharmacist to order it. If you're struggling to find Semglee, consider alternatives like Basaglar or Lantus, and ask your doctor about the Viatris Patient Assistance Program if cost is a barrier.
%2C%20Color%3DOriginal.png)
